Clinical trialNCT02684578CompletedPhase 2Interventional

Metformin for the Minimization of Geographic Atrophy Progression in Patients With AMD

SponsorUniversity of California, San FranciscoEnrollment66Age-Related Macular DegenerationDry Macular DegenerationGeographic AtrophyMacular Degeneration, Age-Related

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to determine whether metformin, an FDA-approved drug for the treatment of type II diabetes, is a safe and effective treatment to decrease the progression of geographic atrophy in non-diabetic patients with Age-related Macular Degeneration (AMD).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Jay M Stewart, MD
University of California, San Francisco
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

12 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of California, Davis
Davis, California, United States
Palo Alto Veteran Affairs Medical Center
Palo Alto, California, United States
Retinal Consultants Medical Group
Sacramento, California, United States
San Francisco Veteran Affairs Medical Center
San Francisco, California, United States
University of California San Francisco
San Francisco, California, United States
California Retina Consultants
Santa Maria, California, United States
North Bay Vitreoretinal Consultants
Santa Rosa, California, United States
Retina Health Center
Fort Myers, Florida, United States
Northwestern University
Chicago, Illinois, United States
University of Illinois at Chicago
Chicago, Illinois, United States
Oregon Health and Science University
Portland, Oregon, United States
Austin Retina Associates
Austin, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Metformin

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Apr 2016
Primary completion: 30 Apr 2022
Completion: 31 Oct 2022
Last update posted: 9 Jun 2023
Registered enrollment: 66
Registry id: NCT02684578

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.